AWH Key Statistics, Chart & Performance
The current stock price of AWH is 0.082 USD. In the past month the price decreased by -30.51%. In the past year, price decreased by -97.65%.
AWH Latest News, Press Relases and Analysis
AWH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.83 | 224.14B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.61 | 203.30B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.43 | 150.59B | ||
| SYK | STRYKER CORP | 28.18 | 141.95B | ||
| IDXX | IDEXX LABORATORIES INC | 59.7 | 60.12B | ||
| BDX | BECTON DICKINSON AND CO | 13.45 | 55.61B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.72 | 50.29B | ||
| RMD | RESMED INC | 25.84 | 37.34B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.43 | 36.44B | ||
| DXCM | DEXCOM INC | 34.12 | 24.75B | ||
| PODD | INSULET CORP | 71.6 | 23.02B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 12.05 | 19.33B |
Related stock screener links
About AWH
Company Profile
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 66 full-time employees. The company went IPO on 2000-09-29. The firm's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.
Company Info
ASPIRA WOMEN'S HEALTH INC
12117 Bee Caves Road Building Three, Suite 100
Austin TEXAS 78738 US
CEO: Valerie B. Palmieri
Employees: 64
Phone: 15125190400
ASPIRA WOMEN'S HEALTH INC / AWH FAQ
What does AWH do?
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 66 full-time employees. The company went IPO on 2000-09-29. The firm's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.
What is the current price of AWH stock?
The current stock price of AWH is 0.082 USD. The price decreased by -12.49% in the last trading session.
Does AWH stock pay dividends?
AWH does not pay a dividend.
How is the ChartMill rating for ASPIRA WOMEN'S HEALTH INC?
AWH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is AWH stock listed?
AWH stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for AWH stock?
ASPIRA WOMEN'S HEALTH INC (AWH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.99).
What is the ownership structure of ASPIRA WOMEN'S HEALTH INC (AWH)?
You can find the ownership structure of ASPIRA WOMEN'S HEALTH INC (AWH) on the Ownership tab.
AWH Technical Analysis
AWH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AWH. AWH may be in some trouble as it scores bad on both profitability and health.
AWH Financial Highlights
Over the last trailing twelve months AWH reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 44.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -238.46% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AWH Forecast & Estimates
5 analysts have analysed AWH and the average price target is 5.61 USD. This implies a price increase of 6741.46% is expected in the next year compared to the current price of 0.082.
For the next year, analysts expect an EPS growth of 46.73% and a revenue growth 79.1% for AWH